162 related articles for article (PubMed ID: 24968154)
21. Human Papillomavirus Infection and Vaccination.
Valentino K; Poronsky CB
J Pediatr Nurs; 2016; 31(2):e155-66. PubMed ID: 26586310
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.
Aljunid S; Maimaiti N; Nur AM; Noor MRM; Wan Puteh SE
BMC Public Health; 2016 Jan; 16():71. PubMed ID: 26803814
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
24. Human Papillomavirus Vaccines: Successes and Future Challenges.
Perez S; Zimet GD; Tatar O; Stupiansky NW; Fisher WA; Rosberger Z
Drugs; 2018 Sep; 78(14):1385-1396. PubMed ID: 30269207
[TBL] [Abstract][Full Text] [Related]
25. Identification of determinants associated with uptake of the first dose of the human papillomavirus vaccine in Denmark.
Amdisen L; Kristensen ML; Rytter D; Mølbak K; Valentiner-Branth P
Vaccine; 2018 Sep; 36(38):5747-5753. PubMed ID: 30111513
[TBL] [Abstract][Full Text] [Related]
26. Human papilloma virus vaccination in Nepal: an initial experience in Nepal.
Singh Y; Shah A; Singh M; Verma S; Shrestha BM; Vaidya P; Nakarmi RP; Shrestha SB
Asian Pac J Cancer Prev; 2010; 11(3):615-7. PubMed ID: 21039025
[TBL] [Abstract][Full Text] [Related]
27. HPV Vaccine utilization, Alberta 2008/09-2013/14 School year.
Liu XC; Bell CA; Simmonds KA; Russell ML; Svenson LW
BMC Infect Dis; 2016 Jan; 16():15. PubMed ID: 26759056
[TBL] [Abstract][Full Text] [Related]
28. The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa.
Snyman LC; Dreyer G; Visser C; Botha MH; van der Merwe FH
S Afr Med J; 2015 Mar; 105(3):191-4. PubMed ID: 26294825
[TBL] [Abstract][Full Text] [Related]
29. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
Watson M; Shaw D; Molchanoff L; McInnes C
Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
[TBL] [Abstract][Full Text] [Related]
30. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
[TBL] [Abstract][Full Text] [Related]
31. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
[TBL] [Abstract][Full Text] [Related]
32. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
33. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing uptake of HPV vaccination among girls in Germany.
Schülein S; Taylor KJ; König J; Claus M; Blettner M; Klug SJ
BMC Public Health; 2016 Sep; 16():995. PubMed ID: 27645711
[TBL] [Abstract][Full Text] [Related]
35. Feasibility of delivering HPV vaccine to girls aged 10 to 15 years in Uganda.
Mugisha E; LaMontagne DS; Katahoire AR; Murokora D; Kumakech E; Seruyange R; Tsu VD
Afr Health Sci; 2015 Mar; 15(1):33-41. PubMed ID: 25834528
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
37. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
Moss JL; Reiter PL; Brewer NT
Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
[TBL] [Abstract][Full Text] [Related]
39. Study protocol for assessing knowledge, attitudes and belief towards HPV vaccination of parents with children aged 9-14 years in rural communities of North West Cameroon: a qualitative study.
Elit L; Ngalla C; Afugchwi GM; Tum E; Fokom-Domgue J; Nouvet E
BMJ Open; 2022 Aug; 12(8):e062556. PubMed ID: 36002223
[TBL] [Abstract][Full Text] [Related]
40. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]